News about Market

Knight Therapeutics Signs Latin America Deal for Mogamulizumab

Knight Therapeutics will seek regulatory approval and commercialise mogamulizumab in Brazil, Mexico, Colombia and Argentina under its agreement with Kyowa Kirin International.

Market | 30/09/2026 | By News Bureau

Biodeal Acquires Biological E Facility for Sterile Injectables

Biodeal Pharmaceuticals acquires a Biological E facility, adding 135 million-unit annual capacity, with its Carbapenem line now operational and validated.

Market | 30/09/2026 | By News Bureau

Organon Canada Expands Nduvra Use to Atopic Dermatitis

Organon Canada expands the use of Nduvra to moderate to severe atopic dermatitis, marking the second approved indication for tapinarof cream in the country.

Market | 29/09/2026 | By News Bureau |  159

Tolerance Bio Licenses Anti-IL-33 Antibody TLB-33 from Tanabe Pharma

Tolerance Bio plans to advance TLB-33 into Phase 2 development to evaluate its potential in preserving thymic function and supporting immune resilience.

Market | 29/09/2026 | By News Bureau

Merck Licenses SciBrunch's KRAS G12D Inhibitor

Merck enters into exclusive global license agreement with SciBrunch Therapeutics for SPR2015, an investigational oral KRAS G12D (ON) inhibitor.

Market | 29/09/2026 | By News Bureau

Chhattisgarh Plans Medicity and Pharma Park

Chhattisgarh is developing a Medicity and Pharma Park in Naya Raipur to strengthen healthcare infrastructure, pharmaceutical manufacturing, investment and employment.

Market | 28/09/2026 | By News Bureau |  105

Amneal Launches FDA-Approved Lanreotide Injection in the US

Amneal Pharmaceuticals has launched lanreotide injection in the US following FDA approval, expanding its complex injectable medicines portfolio.

Market | 28/09/2026 | By News Bureau

AstraZeneca's Imfinzi Combo Gets US Priority Review for MIBC

AstraZeneca’s Imfinzi and enfortumab vedotin combination has received US FDA Priority Review based on positive Phase 3 VOLGA results in muscle-invasive bladder cancer.

Market | 28/09/2026 | By News Bureau

Gossamer Bio Submits First NDA for Seralutinib in PAH

Gossamer Bio has filed an NDA for seralutinib, supported by Phase 3 PROSERA and Phase 2 TORREY study data.

Market | 25/09/2026 | By News Bureau

FDA Panel Backs GRAIL's Galleri Multi-Cancer Detection Test

The US Food and Drug Administration advisory panel backed Galleri’s safety and voted that its benefits outweigh risks, while six of 10 members supported its effectiveness.

Market | 25/09/2026 | By News Bureau